Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 5, 2015, Pages 195-202

  Weng, Liming ^a   Quinlivan, Eoin ^a   Gong, Yan ^a   Beitelshees, Amber L ^b   Shahin, Mohamed H ^a   Turner, Stephen T ^c   Chapman, Arlene B ^d   Gums, John G ^a   Johnson, Julie A ^a   Frye, Reginald F ^a   Garrett, Timothy J ^a   Cooper DeHoff, Rhonda M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Information Technology   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINO ACID; BRANCHED CHAIN AMINO ACID; GLUCOSE; URIC ACID; ANTIHYPERTENSIVE AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AFRICAN AMERICAN; AGE; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIAC PATIENT; COHORT ANALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; EUROPEAN AMERICAN; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SMOKING; TANDEM MASS SPECTROMETRY; URIC ACID BLOOD LEVEL; WEIGHT; ADOLESCENT; AGED; ANALYSIS; BLOOD; CAUCASIAN; CLINICAL TRIAL; COMPLICATION; ETHNOLOGY; GENETICS; HYPERTENSION; MASS SPECTROMETRY; MIDDLE AGED; MULTICENTER STUDY; PHARMACOGENETICS; STATISTICAL MODEL; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AMINO ACIDS, AROMATIC; AMINO ACIDS, BRANCHED-CHAIN; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FASTING; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MASS SPECTROMETRY; METABOLIC SYNDROME X; MIDDLE AGED; PHARMACOGENETICS; UNITED STATES; YOUNG ADULT;

EID: 84929571972     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2014.0132     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: US Department of Health and Human Services, 2014.
2. Henry P, Thomas F, Benetos A, et al. Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension 2002;40:458-463.
3. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 2007;30:228-233.
4. Schutta MH. Diabetes and hypertension: Epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr 2007; 2:124-130.
5. Cheung BM, Li C. Diabetes and hypertension: Is there a common metabolic pathway? Curr Atheroscler Rep 2012; 14:160-166.
6. Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm. Am J Med 2005; 118:939-947.
7. Davidson MB. Metabolic syndrome/insulin resistance syndrome/pre-diabetes: New section in diabetes care. Diabetes Care 2003;26:3179.
8. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2012;59:635-643.
9. Vinayavekhin N, Homan EA, Saghatelian A. Exploring disease through metabolomics. ACS Chem Biol 2010;5:91-103.
10. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453.
11. Walford GA, Davis J, Warner AS, et al. Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus. Metabolism 2013;62:1772-1778.
12. Wurtz P, Soininen P, Kangas AJ, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care 2013;36:648-655.
13. McCormack SE, Shaham O, McCarthy MA, et al. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes 2013;8:52-61.
14. Johnson JA, Boerwinkle E, Zineh I, et al. Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009;157:442-449.
15. Hamadeh IS, Langaee TY, Dwivedi R, et al. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther 2014;96:175-181.
16. Cooper-DeHoff RM, Wen S, Beitelshees AL, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2010;55:61-68.
17. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
18. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26: 3160-3167.
19. Lewanczuk R. Hypertension as a chronic disease: What can be done at a regional level? Can J Cardiol 2008;24:483-484.
20. Cooper-Dehoff RM, Hou W, Weng L, et al. Is diabetes mellitus-linked amino acid signature associated with betablocker-induced impaired fasting glucose? Circ Cardiovasc Genet 2014;7:199-205.
21. Freudenberg A, Petzke KJ, Klaus S. Comparison of highprotein diets and leucine supplementation in the prevention of metabolic syndrome and related disorders in mice. J Nutr Biochem 2012;23:1524-1530.
22. Zhang Y, Guo K, LeBlanc RE, et al. Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes 2007;56:1647-1654.
23. Nairizi A, She P, Vary TC, et al. Leucine supplementation of drinking water does not alter susceptibility to diet-induced obesity in mice. J Nutr 2009;139:715-719.
24. Guo F, Cavener DR. The GCN2 eIF2alpha kinase regulates fatty-acid homeostasis in the liver during deprivation of an essential amino acid. Cell Metab 2007;5:103-114.
25. Aung K, Lorenzo C, Hinojosa MA, et al. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. J Clin Endocrinol Metab 2014;99:462-468.
26. Hanley AJ, Wagenknecht LE, D'Agostino RB Jr, et al. Identification of subjects with insulin resistance and betacell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 2003;52:2740-2747.
27. Alexander CM, Landsman PB, Grundy SM. Metabolic syndrome and hyperglycemia: Congruence and divergence. Am J Cardiol 2006;98:982-985.
28. Lackey DE, Lynch CJ, Olson KC, et al. Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. Am J Physiol Endocrinol Metab 2013;304:E1175-E1187.
29. Kimberly WT, Wang Y, Pham L, et al. Metabolite profiling identifies a branched chain amino acid signature in acute cardioembolic stroke. Stroke 2013;44:1389-1395.
30. Magnusson M, Lewis GD, Ericson U, et al. A diabetespredictive amino acid score and future cardiovascular disease. Eur Heart J 2013;34:1982-1989.
31. Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. World J Gastroenterol 2013;19:7620-7629.
32. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, et al. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009;15:280-288.
33. Khoury JC, Kleindorfer D, Alwell K, et al. Diabetes mellitus: A risk factor for ischemic stroke in a large biracial population. Stroke 2013;44:1500-1504.
34. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: The role of hypoglycemia. Circulation 2011;123:342-348.
35. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: A global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008;48: 653-683.
36. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311-326.
37. Wek SA, Zhu S, Wek RC. The histidyl-tRNA synthetaserelated sequence in the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids. Mol Cell Biol 1995;15:4497-4506.
38. Carraro V, Maurin AC, Lambert-Langlais S, et al. Amino acid availability controls TRB3 transcription in liver through the GCN2/eIF2alpha/ATF4 pathway. PLoS One 2010;5:e15716.
39. Lynch CJ, Role of leucine in the regulation of mTOR by amino acids: Revelations from structure-activity studies. J Nutr 2001;131:861S-865S.
40. Leclerc I, Rutter GA. AMP-activated protein kinase: A new beta-cell glucose sensor?: Regulation by amino acids and calcium ions. Diabetes 2004;53(Suppl 3):S67-S74.
41. Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 2001;276:38052-38060.